"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

By editing the polymers of discarded plastics, chemists have found a way to generate new macromolecules with more valuable properties than those of the starting material. Upcycling may help remedy the ...

The scientific team at the laboratory is headed by a group of women with a track record in genomic science, molecular ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...